A year ago, Alzheimer’s researchers expressed guarded optimism. The first new drug in nearly two decades was about to hit the market, and pharmaceutical companies had potentially stronger drugs in the pipeline.
But the controversial drug Aduhelm has barely been prescribed amid Medicare payment restrictions. And researchers now face questions about whether they’ve wasted time and federal grant money on a dead end after Science magazine reported last week that an influential 2006 study relied on fabricated images to support its conclusion. The magazine said the study possibly misdirected Alzheimer’s research for the past 16 years.